Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Bioventus Inc. Class A Common Stock (BVS)

Surgical & Medical Instruments & Apparatus

https://www.bioventus.com

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.

4721 EMPEROR BOULEVARD, SUITE 100
DURHAM, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/11/2021

Market Cap

558,651,724

Shares Outstanding

62,970,000

Weighted SO

62,965,830

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

TIVC --.--%

TLIS --.--%

BJDX --.--%

HSCS --.--%

NUWE --.--%

BBLG --.--%

NAOV --.--%

VVOS --.--%

RPID --.--%

Beta

0.8390

Last Div

0.0000

Range

2.821-8.68

Chg

0.2900

Avg Vol

554438

Mkt Cap

558651724

Exch

NASDAQ

Country

US

Phone

919 474 6700

DCF Diff

4.1079

DCF

4.4221

Div Yield

0.0000

P/S

1.0405

EV Multiple

13.0783

P/FV

3.6371

Div Yield %

0.0000

P/E

-13.0828

PEG

-1.1021

Payout

0.0000

Current Ratio

1.3345

Quick Ratio

0.9560

Cash Ratio

0.1382

DSO

93.3454

DIO

172.2465

Op Cycle

265.5920

DPO

48.0468

CCC

217.5452

Gross Margin

0.6542

Op Margin

0.0345

Pretax Margin

-0.1138

Net Margin

-0.0782

Eff Tax Rate

0.1077

ROA

-0.0530

ROE

-0.2493

ROCE

0.0330

NI/EBT

0.6865

EBT/EBIT

-3.3034

EBIT/Rev

0.0345

Debt Ratio

0.4877

D/E

2.5595

LT Debt/Cap

0.6955

Total Debt/Cap

0.7191

Int Coverage

0.4551

CF/Debt

0.0260

Equity Multi

5.2484

Rec Turnover

3.9102

Pay Turnover

7.5968

Inv Turnover

2.1191

FA Turnover

12.6913

Asset Turnover

0.6777

OCF/Share

0.1567

FCF/Share

0.1023

Cash/Share

0.4995

OCF/Sales

0.0187

FCF/OCF

0.6530

CF Coverage

0.0260

ST Coverage

0.2412

CapEx Coverage

2.8823

Div&CapEx Cov

2.8823

P/BV

3.6371

P/B

3.6371

P/S

1.0405

P/E

-13.0828

P/FCF

85.2383

P/OCF

54.6997

P/CF

54.6997

PEG

-1.1021

P/S

1.0405

EV Multiple

13.0783

P/FV

3.6371

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 10, 05:30 Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights GlobeNewswire Inc. Jan 18, 16:15 Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility GlobeNewswire Inc. Jan 12, 16:15 Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole GlobeNewswire Inc. Dec 19, 16:30 Bioventus Names Robert Claypoole as President and Chief Executive Officer Benzinga Dec 07, 15:35 MedTech Bioventus' Stabilization Sparks Analyst Confidence, Earns Upgrade And Price Target Boost

Revenue Product Segmentation